Related Experiment Videos
Citrullinemia. Clinical experience with 23 cases
1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
The Turkish Journal of Pediatrics
|July 25, 1998
Summary
Citrullinemia treatment outcomes were poor, especially in neonatal cases, with high mortality and unsatisfactory neurological results. Early diagnosis and therapy are crucial for improving prognosis and quality of life in citrullinemia patients.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Citrullinemia is a rare urea cycle disorder.
- It leads to hyperammonemia and severe health consequences.
Purpose of the Study:
- To evaluate the clinical outcomes of citrullinemia patients.
- To identify factors influencing prognosis and quality of life.
Main Methods:
- Retrospective study of 23 citrullinemia patients over 20 years.
- Analysis of treatment protocols including protein restriction, medications, and supportive care.
- Assessment of mortality and neurological outcomes.
Main Results:
- 14 out of 23 patients died, predominantly those with neonatal-onset citrullinemia.
- Survivors exhibited unsatisfactory neurological outcomes.
- Treatment included protein restriction, sodium benzoate, arginine, and for neonatal cases, exchange transfusions/peritoneal dialysis.
Conclusions:
- The prognosis for citrullinemia remains challenging, particularly for neonatal forms.
- Early diagnosis and prompt, appropriate therapeutic interventions are essential.
- Improving treatment strategies may enhance patient survival and quality of life.